IRIS
MATUCCI CERINIC, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 14.954
AS - Asia 12.658
EU - Europa 11.826
SA - Sud America 2.185
Continente sconosciuto - Info sul continente non disponibili 1.057
AF - Africa 195
OC - Oceania 27
Totale 42.902
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.178
RU - Federazione Russa 6.309
SG - Singapore 5.349
CN - Cina 3.615
IT - Italia 2.595
BR - Brasile 1.806
HK - Hong Kong 1.620
VN - Vietnam 883
RO - Romania 729
FR - Francia 719
BD - Bangladesh 404
CA - Canada 387
DE - Germania 352
GB - Regno Unito 269
NL - Olanda 190
IN - India 170
MX - Messico 135
SE - Svezia 133
AR - Argentina 125
FI - Finlandia 89
AT - Austria 88
PL - Polonia 85
TR - Turchia 82
JP - Giappone 69
EC - Ecuador 64
ES - Italia 62
JM - Giamaica 61
ID - Indonesia 60
IQ - Iraq 57
CO - Colombia 54
ZA - Sudafrica 54
MY - Malesia 42
CR - Costa Rica 41
VE - Venezuela 39
UA - Ucraina 36
MA - Marocco 35
UZ - Uzbekistan 35
PK - Pakistan 31
HN - Honduras 27
CL - Cile 26
LT - Lituania 26
PY - Paraguay 26
AE - Emirati Arabi Uniti 24
NI - Nicaragua 24
NP - Nepal 24
SA - Arabia Saudita 24
PH - Filippine 23
EG - Egitto 22
TN - Tunisia 22
AU - Australia 18
CH - Svizzera 18
GT - Guatemala 18
IL - Israele 18
TT - Trinidad e Tobago 18
UY - Uruguay 17
PE - Perù 16
JO - Giordania 15
PT - Portogallo 15
SV - El Salvador 15
TH - Thailandia 15
TW - Taiwan 14
DZ - Algeria 13
KE - Kenya 13
IE - Irlanda 12
SN - Senegal 12
MD - Moldavia 11
BE - Belgio 10
DO - Repubblica Dominicana 10
AL - Albania 9
AZ - Azerbaigian 9
LV - Lettonia 9
BH - Bahrain 8
KZ - Kazakistan 8
BB - Barbados 7
BG - Bulgaria 7
CZ - Repubblica Ceca 7
EE - Estonia 7
GR - Grecia 7
HU - Ungheria 7
KR - Corea 7
OM - Oman 7
PS - Palestinian Territory 7
BO - Bolivia 6
BS - Bahamas 6
CY - Cipro 6
ET - Etiopia 6
IR - Iran 6
NZ - Nuova Zelanda 6
RS - Serbia 6
AM - Armenia 5
LU - Lussemburgo 5
PA - Panama 5
AO - Angola 4
QA - Qatar 4
BN - Brunei Darussalam 3
BY - Bielorussia 3
DK - Danimarca 3
GD - Grenada 3
GY - Guiana 3
KG - Kirghizistan 3
Totale 41.787
Salva come PNG Salva come JPEG
Città #
Dallas 2.998
Singapore 2.620
San Jose 2.119
Ashburn 2.006
Hong Kong 1.601
Moscow 1.440
Council Bluffs 704
Hefei 629
Shanghai 625
Milan 563
Lauterbourg 547
Phoenix 419
Beijing 415
Ho Chi Minh City 322
Santa Clara 297
New York 276
Los Angeles 237
Rome 196
Hanoi 193
São Paulo 157
Atlanta 118
Miano 118
Nuremberg 109
Montreal 96
Brooklyn 87
Chicago 81
North Bergen 75
Rio de Janeiro 75
Munich 74
Orem 74
Denver 70
Warsaw 67
Toronto 65
Florence 64
Naples 64
Guangzhou 61
Boardman 59
Mexico City 56
San Francisco 56
Tokyo 56
Amsterdam 54
Omaha 52
Stockholm 51
Buffalo 50
Chennai 47
Bologna 46
Da Nang 46
London 46
Boston 42
Houston 41
Washington 40
Brasília 39
Frankfurt am Main 39
Turin 39
Philadelphia 36
Johannesburg 35
Palermo 33
Vienna 33
Assago 32
Belo Horizonte 32
Lappeenranta 32
San José 32
Helsinki 31
Hangzhou 30
Shenzhen 30
Tashkent 29
Charlotte 28
St Louis 28
Tianjin 28
Haiphong 27
Guayaquil 26
Las Vegas 25
Manchester 25
Seattle 25
Princeton 24
The Dalles 24
Turku 24
Bari 23
Dhaka 23
Kingston 23
Porto Alegre 23
Istanbul 22
Baghdad 21
Kuala Lumpur 21
Paris 21
Poplar 21
Managua 20
Mumbai 20
Clifton 19
Curitiba 19
Hải Dương 19
Miami 19
Secaucus 19
Ankara 18
Cincinnati 18
Lawrence 18
Salvador 18
The Bronx 18
New Delhi 17
Quito 17
Totale 21.647
Salva come PNG Salva come JPEG
Nome #
Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis 1.058
ENDOMETRIOSI E MALATTIE REUMATICHE: LA PUNTA DELL’ICEBERG DEI NUMEROSI DISTURBI MESTRUALI IN CORSO DI MALATTIA REUMATICA 610
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study 580
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 478
Phenotyping by persistent inflammation in systemic sclerosis associated interstitial lung disease: A EUSTAR database analysis 419
The Performance of Pulmonary Function Tests in Predicting Systemic Sclerosis—Interstitial Lung Disease in the European Scleroderma Trial and Research Database 411
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 402
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 361
GLI INTERVENTI INFERMIERISTICI RIVOLTI AI PAZIENTI AFFETTI DA MALATTIE REUMATICHE SOTTOPOSTI A TERAPIA CON FARMACI BIOLOGICI: REVISIONE SISTEMATICA DELLA LETTERATURA 297
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 245
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 177
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 166
The Italian version of the Hand Mobility in Scleroderma (HAMIS) test: evidence for its validity and reliability 166
Clinical significance of the anti-Nucleolar Organizer Region 90 antibodies (NOR90) in systemic sclerosis: Analysis of the European Scleroderma Trials and Research (EUSTAR) cohort and a systematic literature review 154
"Atlas of Capilaroscopy in Rheumatic Diseases" - Chapter: The microcirculation and Rheumatic Diseases 153
EULAR recommendations for the treatment of systemic sclerosis: 2023 update 146
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 145
Systemic amyloidosis: a challenge for the rheumatologist 139
"Autoimmunity" - Chapter: Autoantibodies in systemic sclerosis 136
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 135
A Multinational Survey Investigating the Unmet Needs and Patient Perspectives Concerning Proton Pump Inhibitors in Systemic Sclerosis 132
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 132
Exercise Stress Echocardiography of the Right Ventricle and Pulmonary Circulation 131
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative 129
Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: A single-centre prospective study 129
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation 129
The Potential Role of Butyrate in the Pathogenesis and Treatment of Autoimmune Rheumatic Diseases 128
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 127
A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study 123
Efficacy and Safety of Lenabasum, a Cannabinoid Type 2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis 123
A custom-made splint is useful in the treatment of Osteoarthritis of the trapeziometacarpal joint 122
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 121
Very early and early diagnosis of systemic sclerosis 121
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 121
A comparison of two podiatric protocols for metatarsalgia in patients with rheumatoid arthritis and osteoarthritis 118
A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis 117
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 115
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 115
Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database 114
Systemic pharmacological treatment of digital ulcers in systemic sclerosis: a systematic literature review 113
Managing complicated digital ulcers 113
A contribution to the debate about the possible different clinical severity between hemophilia A and B 113
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 113
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 112
A 24-Week, Phase IIa, Randomized, Double-Blind, Placebo-Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis 112
A multi-national survey to identify clinicians’ perspectives concerning Proton Pump inhibitors in patients with systemic sclerosis 111
The COVID-19 pandemic highlights the need for a psychological support in systemic sclerosis patients 111
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs] 110
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 108
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative 108
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 107
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 107
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity 106
Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data 103
Historical perspective of scleroderma 103
"Epigenetic in rheumatic diseases" - Chapter: Epigenetics in systemic sclerosis 103
Infection-Associated Flares in Systemic Lupus Erythematosus 102
QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases 102
A combined rehabilitative program is efficacious in the treatment of hands of Systemic Sclerosis patients 102
Integrative Transcriptomic Analysis of Peripheral Blood Monocytes in Systemic Sclerosis and Shared Pathogenic Pathways in Autoimmune Diseases 102
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 102
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 102
Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies 101
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 101
Clinical implications of interstitial pneumonia with autoimmune features diagnostic criteria in idiopathic pulmonary fibrosis: A case control study 101
[Vasculogenesis and angiogenesis: vascular damage in systemic sclerosis] 99
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 99
Stressful life events at the onset and during the evolution of systemic sclerosis 99
Editorial: Cardiovascular involvement in autoimmune diseases, volume II 99
A genetic variant located in the promoter of the uPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 98
Towards a comprehensive approach to the management and prognosis of systemic sclerosis's patients: The role of comorbidities in the SPRING-SIR registry 98
Extracellular vesicles and interstitial lung disease in systemic sclerosis: State of the art! 98
A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia 97
Alfabetizzazione sanitaria e pazienti affetti da Sclerosi Sistemica 97
Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS) 97
Riabilitazione dell’articolazione temporomandibolare (atm) in pazienti con sclerosi sistemica (ssc): confronto tra due protocolli. Risultati preliminari 96
Performance of ultra-high-frequency ultrasound in the evaluation of skin involvement in systemic sclerosis: A preliminary report 96
Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSScipher inception cohort study 96
Unraveling the Pathogenesis of Calcinosis in Systemic Sclerosis: A Molecular and Clinical Insight 94
Combination of denosumab and biologic DMARDs in inflammatory muscle-skeletal diseases and connective tissue diseases 94
18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis 94
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 94
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 93
Secukinumab is not associated with cancer recurrence or progression in patients with spondyloarthritis and history of neoplastic disease 92
EFFICACY OF A SELF-TREATMENT PROTOCOL FOR FACE AND TEMPOROMANDIBULAR JOINTS REHABILITATION IN SYSTEMIC SCLEROSIS 92
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis 92
The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs 91
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 91
Long-term outcomes of COVID-19 vaccination in patients with rare and complex connective tissue diseases: The ERN-ReCONNET VACCINATE study 90
Hand Function in Scleroderma 90
Interstitial lung disease in limited cutaneous systemic sclerosis patients: never let your guard down 90
Soluble guanylate cyclase stimulation fosters angiogenesis and blunts myofibroblast-like features of systemic sclerosis endothelial cells 89
Raynaud's phenomenon, digital ulcers and nailfold capillaroscopy 89
Doppler ultrasound, a noninvasive tool for the study of mesenteric arterial flow in systemic sclerosis: a cross-sectional study of a patient cohort with review and meta-analysis of the literature 88
Beyond very early systemic sclerosis: deciphering pre‑scleroderma and its trajectories to open new avenues for preventive medicine 87
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 87
A versatile role for lung ultrasound in systemic autoimmune rheumatic diseases related pulmonary involvement: a narrative review 86
ASSESSMENT OF HEALTH LITERACY IN A COHORT OF SYSTEMIC SCLEROSIS (SSC) PATIENTS 86
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study 86
The combination of connective tissue massage, Kabat's technique, kinesitherapy and home exercise is helpful in face rehabilitation of Systemic Sclerosis patients 86
Totale 14.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 204.996
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 204.996
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202227 0 0 0 3 1 3 1 0 0 16 1 2
2022/2023170 42 28 9 1 3 16 29 20 15 0 6 1
2023/20241.249 4 9 14 20 18 574 222 176 10 26 48 128
2024/20258.238 986 202 92 159 357 567 1.513 542 1.358 1.183 612 667
2025/202626.348 1.984 2.651 2.404 2.679 1.577 670 3.092 1.584 5.682 1.366 998 1.661
2026/20276.854 806 1.816 1.660 2.572 0 0 0 0 0 0 0 0
Totale 42.902